Fujifilm Kyowa Kirin and Mylan EPD Launch Adalimumab Biosimilar in Japan

Shots:

• This is the first launch of a biosimilar to Humira in Japan. Mylan EPD will lead the commercialization of the biosimilar
• The launch is a testament to the power of Viatris’ unique Global Healthcare Gateway which helps partners to further expand patient access to more affordable medicines across the globe
• In 2018, Fujifilm Kyowa Kirin Biologics and Viatris collaborated for the commercialization of Hulio in the EU and Viatris has commercialized the product in 20+ countries across the region. In 2019, the companies expanded the partnership globally

Click here ­to­ read full press release/ article | Ref: Biosimilar Development | Image: PRNewswire